A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
Description
Access to the investigational medication (ravulizumab) will be available to participants following the double-blinded portion of the trial.
Details
Age
Adult
Eligibility
Adults with biopsy proven IgAN (immunoglobulin A nephropathy)
Locations
Outpatient CTRC
Renal Research Center
University of Colorado Hospital
Principal Investigator
Judith Blaine
Study ID
Protocol Number: 24-0436
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers